Clinical trials
Chronic Liver Disease and Cirrhosis clinical trials
Below are recruiting chronic liver disease and cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07662889Enrolling by invitation
Comparing two types of dialysis for kidney failure
This trial compares a newer type of dialysis called hemodiafiltration with standard hemodialysis to see if it improves certain health measures in people with end-stage kidney disease. It may help determine which method works better for long-term treatment.
Lahore, Punjab ProvinceAges 18–70 - NCT06824974Recruiting
Time-restricted eating for liver disease or cancer
This study tests whether combining time-restricted eating with healthy eating helps people with metabolic liver disease, cirrhosis, or early-stage liver cancer. If you are overweight and currently fast less than 12 hours at night, this diet approach might improve your health.
La Jolla, CaliforniaAges 18 years+ - NCT06883578Recruiting
Effect of a low valine diet on body weight and metabolism
This trial studies if a diet low in valine, a building block of protein, can help people with excess weight lose weight and improve their metabolic health. It may offer an alternative approach for weight loss.
Shanghai, Shanghai MunicipalityAges 16–80 - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT05689645RecruitingPhase 2
Drug trial for liver injury or liver failure
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
Beijing, Beijing MunicipalityAges 18–60 - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT05956379Enrolling by invitation
Exercise and monitoring study for chronic hepatitis B with fatty liver
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
Taipei, Zhongzheng Dist.Ages 18–70 - NCT06908785Recruiting
Blood test to predict bleeding risk after procedures in cirrhosis
This trial is testing if a special blood test called ROTEM can help doctors predict the risk of bleeding after high-risk procedures in people with cirrhosis. It aims to improve safety and guide treatment decisions.
Santander, CantabriaAges 18–65 - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT06496191Recruiting
Fecal transplant for alcohol use in cirrhotics
This trial tests whether a fecal microbiota transplant (FMT) can help people with alcohol-related cirrhosis who are still drinking. It aims to see if FMT can reduce alcohol cravings and improve liver health.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75 - NCT06968234Recruiting
Liver disease breath test study
This study uses a special breath test to learn about chronic liver disease. If you have liver disease or cirrhosis, you may be able to help by providing a breath sample.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07472049Recruiting
Imaging plaque activity in peripheral artery disease
This trial studies plaque activity in leg arteries using a new imaging method to understand artery disease better. It may help people with peripheral artery disease get more targeted treatment.
Edinburgh, MidlothianAges 18 years+ - NCT05325099RecruitingPhase 1/Phase 2
Azacitidine to help prevent kidney injury after heart surgery
This early-phase study tests whether azacitidine (a medication that changes how cells read genes) can lower the risk of acute kidney injury after cardiac surgery, especially in people already at risk along the chronic kidney disease (CKD) pathway. It aims to protect kidney function during the vulnerable period after surgery.
TaipeiAges 20 years+ - NCT05213598Recruiting
Biomarker study for liver disease after Fontan surgery
This study looks for blood and/or test markers that can better show how severe liver disease is in people who had the Fontan heart procedure. It also involves medical imaging and/or a liver biopsy or related procedures to help evaluate those markers.
Bethesda, MarylandAges 18–100 - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Birmingham, AlabamaAges 18 years+ - NCT06567990Recruiting
Type 2 diabetes and fatty liver: new tests for disease tracking
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
DijonAges 40–80 - NCT05525507RecruitingPhase 1
Test early immune-tolerance treatment for matched kidney transplant patients
This Phase 1 study tests a treatment plan given after a kidney transplant to help the immune system stay calm and reduce the risk of rejection. Participants must have a well-functioning kidney transplant from a closely matched living donor and meet health and safety requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT05439226Recruiting
Diet plan targeting liver fat for type 2 diabetes
This study tests whether a Chinese medical nutrition therapy diet can reduce liver fat and help manage type 2 diabetes in people who also have fatty liver. You may be asked to follow a specific eating plan and keep your diabetes care stable during the study.
Yichang, HubeiAges 18–75 - NCT07046819RecruitingPhase 2
Tirzepatide for liver disease linked to alcohol use
This trial tests if tirzepatide, a medication that helps with weight and blood sugar, can improve liver health in people with alcohol use disorder who also have fatty liver disease. It aims to reduce liver fat and related risks.
Bethesda, MarylandAges 21–100 - NCT06531824RecruitingPhase 3
Heart and kidney protection study for chronic kidney disease
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
Huntsville, AlabamaAges 18 years+ - NCT07527910RecruitingPhase 2
Study of ALN-PNP with or without tirzepatide for fatty liver disease
This trial tests a new drug, ALN-PNP, alone or with tirzepatide in people with a specific genetic type of fatty liver disease. It aims to see if the combination reduces liver fat.
Coronado, CaliforniaAges 18–75
Hear when a new Chronic Liver Disease and Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease and cirrhosis?
- Yes. Clin2 currently lists 203 recruiting chronic liver disease and cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease and cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease and cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.